Data / New clinical trials / Leukemia, Myeloid, Acute

Leukemia, Myeloid, Acute trials: 390 new since Nov 2024

Name: New Leukemia, Myeloid, Acute clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Leukemia, Myeloid, Acute clinical trials: 390 rows for $19.50, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 15 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/leukemia-myeloid-acute, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

390 clinical studies in Leukemia, Myeloid, Acute were first posted on ClinicalTrials.gov from November 15, 2024 to November 9, 2026; 69 have an industry sponsor and 338 are recruiting or about to. The newest, NCT07926607, was posted on November 9, 2026: Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (Second Affiliated Hospital of Nanchang University).

The request: Every new Leukemia, Myeloid, Acute clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

390New trials
69Industry sponsored
338Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 390, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07926607	Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia	Second Affiliated Hospital of Nanchang University	Phase 1/2	Not yet recruiting	Acute Myeloblastic Leukemia	55	China	clinicaltrials.gov
November 9, 2026	NCT07925554	Interferon-α Maintenance in Favorable-Risk AML	Peking University People's Hospital	Phase 2	Recruiting	AML (Acute Myeloid Leukemia)	30	China	clinicaltrials.gov
November 9, 2026	NCT07925190	A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 3	Not yet recruiting	Acute Myeloblastic Leukaemia	318	China	clinicaltrials.gov
November 6, 2026	NCT07923071	A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment	Syndax Pharmaceuticals	Phase 1	Not yet recruiting	Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia, Refractory Leukemia, Relapsed Leukemia	18		clinicaltrials.gov
November 5, 2026	NCT07919119	Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT	Institute of Hematology & Blood Diseases Hospital, China	Observational	Not yet recruiting	Measurable Residual Disease, Acute Myeloid Leukemia	169	China	clinicaltrials.gov
November 3, 2026	NCT07912684	The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized...	Gruppo Italiano Malattie EMatologiche dell'Adulto	Not applicable	Recruiting	Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma	75	Italy	clinicaltrials.gov
November 2, 2026	NCT07909733	Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT	University of Wisconsin, Madison	Phase 1	Not yet recruiting	High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid...	27	United States	clinicaltrials.gov
October 29, 2026	NCT07905027	A Study of CLEC2A CAR T for Pediatric and Adult Patients With Relapsed or Refractory AML	Seattle Children's Hospital	Phase 1	Not yet recruiting	Acute Myeloid Leukemia, Acute Myeloid Leukaemia Recurrent, Acute Myeloid Leukaemia Refractory	20	United States	clinicaltrials.gov
October 29, 2026	NCT07904884	MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )	First Affiliated Hospital of Zhejiang University	Not applicable	Not yet recruiting	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Acute Myeloid Leukemia	310	China	clinicaltrials.gov
October 27, 2026	NCT07897136	CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia	Liping Dou	Phase 1	Not yet recruiting	Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia	12	China	clinicaltrials.gov
October 26, 2026	NCT07895901	Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry	University Hospital, Strasbourg, France	Observational	Recruiting	Acute Myeloid Leukemia, Myeloid Hematological Malignancies, Normal Hematopoietic Stem and Progenitor Cells	50	France	clinicaltrials.gov
October 16, 2026	NCT07877610	CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults	Fondazione Matilde Tettamanti Menotti De Marchi Onlus	Phase 1/2	Recruiting	AML (Acute Myeloid Leukemia), BPDCN	18	Italy	clinicaltrials.gov
October 15, 2026	NCT07874737	Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia	The Affiliated People's Hospital of Ningbo University	Phase 2	Not yet recruiting	Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)	20		clinicaltrials.gov
October 14, 2026	NCT07874100	This Study Aims to Improve the Stratification of Patients With Acute Myeloid Leukemia to Enable More Personalized and Effective Treatments...	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	Not applicable	Recruiting	Acute Myeloid Leukemia	420	Italy	clinicaltrials.gov
October 14, 2026	NCT07873827	KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies	Stemline Therapeutics, Inc.	Phase 1/2	Not yet recruiting	Hematological Malignancy	115		clinicaltrials.gov
October 9, 2026	NCT07869342	NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study	Peking University People's Hospital	Not applicable	Not yet recruiting	Acute Myeloid Leukemia, Adult	180		clinicaltrials.gov
October 9, 2026	NCT07867704	Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory...	Gruppo Italiano Malattie EMatologiche dell'Adulto	Not applicable	Not yet recruiting	Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult, Acute Promyelocytic Leukemia	75		clinicaltrials.gov
October 9, 2026	NCT07867626	Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML	Rutgers, The State University of New Jersey	Phase 2	Not yet recruiting	Acute Myeloid Leukaemia (AML)	41	United States	clinicaltrials.gov
October 7, 2026	NCT07862517	Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of...	National Cancer Institute (NCI)	Phase 2	Not yet recruiting	Acute Myeloid Leukemia	122		clinicaltrials.gov
October 6, 2026	NCT07861477	Murottal as Adjunctive Intervention in Pediatric	Universitas Airlangga	Not applicable	Completed	Pediatric Cancer, Hematologic Malignancies, Anxiety, Sleep Disturbances in Children, Leukemia (Both ALL and AML)	20	Indonesia	clinicaltrials.gov
September 25, 2026	NCT07841002	CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia	Liping Dou	Phase 1	Not yet recruiting	Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)	12	China	clinicaltrials.gov
September 18, 2026	NCT07828535	Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML	Institute of Hematology & Blood Diseases Hospital, China	Phase 1	Not yet recruiting	Acute Myeloid Leukemia (AML)	30		clinicaltrials.gov
September 16, 2026	NCT07822789	Chidamide in HR-AML	Guangdong Second Provincial General Hospital	Observational	Active not recruiting	Acute Myeloid Leukemia, Maintenance Therapy	33	China	clinicaltrials.gov
September 14, 2026	NCT07819396	Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic...	Fred Hutchinson Cancer Center	Phase 2	Not yet recruiting	Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute...	52	United States	clinicaltrials.gov
September 10, 2026	NCT07814339	Hydrochloroquinine & Decitabine With Venetoclax in AML	Rutgers, The State University of New Jersey	Phase 1	Not yet recruiting	Acute Myeloid Leukemia	18		clinicaltrials.gov
September 10, 2026	NCT07813390	Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure	Guangdong Second Provincial General Hospital	Phase 2	Enrolling by invitation	Acute Myeloid Leukemia (AML)	73	China	clinicaltrials.gov
September 9, 2026	NCT07810829	Prognostic Value of CAR, AFR and Ferritin in Non-M3 AML	Assiut University	Observational	Not yet recruiting	Acute Myeloid Leukemia, Non-M3 Acute Myeloid Leukemia, De Novo Acute Myeloid Leukemia With Multilineage Dysplasia	208		clinicaltrials.gov
September 9, 2026	NCT07809984	Prevention of Oral Mucositis in Adults in With Hematologic Malignancy	Wake Forest University Health Sciences	Not applicable	Not yet recruiting	Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis	206	United States	clinicaltrials.gov
September 4, 2026	NCT07805096	Efficacy of a Smart Holistic Health Care Platform Intervention on Cancer Children and Parents' Bio-Psycho-Social and Spiritual Health	National Defense Medical University, Taiwan	Not applicable	Recruiting	Leukemia (Both ALL and AML), Brain Tumors	120	Taiwan	clinicaltrials.gov
September 3, 2026	NCT07802015	Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish Study of Feasibility, Costs, and Implementation	Zealand University Hospital	Observational	Not yet recruiting	Hematologic Cancer, Acute Myeloid Leukaemia (AML), Hospital At Home, Home-based Chemotherapy	80		clinicaltrials.gov
August 25, 2026	NCT07784309	A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies	Institute of Hematology & Blood Diseases Hospital, China	Phase 1	Enrolling by invitation	Acute T Cell Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory...	13	China	clinicaltrials.gov
August 24, 2026	NCT07783100	Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia	The First Affiliated Hospital of Xiamen University	Phase 2	Recruiting	Relapsed or Refractory Acute Myeloid Leukemia	30	China	clinicaltrials.gov
August 21, 2026	NCT07780565	Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center	Phase 1	Not yet recruiting	Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome	42	United States	clinicaltrials.gov
August 21, 2026	NCT07779031	A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients...	Liping Dou	Phase 1/2	Active not recruiting	Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)	58	China	clinicaltrials.gov
August 20, 2026	NCT07777471	Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia	University of Alabama at Birmingham	Not applicable	Not yet recruiting	Acute Myeloid Leukemia (AML)	40	United States	clinicaltrials.gov
August 19, 2026	NCT07773909	Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Phase 4	Completed	Acute Myeloid Leukemia	24	Bangladesh	clinicaltrials.gov
August 18, 2026	NCT07771803	A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)	Roger Strair	Early phase 1	Recruiting	AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory	20	United States	clinicaltrials.gov
August 18, 2026	NCT07770698	A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia	BeOne Medicines	Phase 1/2	Not yet recruiting	Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric...	30		clinicaltrials.gov
August 13, 2026	NCT07763054	Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients	Haikou Affiliated Hospital of Central South University Xiangya School of Medicine	Observational	Recruiting	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Lymphoma, Multiple Myeloma, Chronic...	30	China	clinicaltrials.gov
August 13, 2026	NCT07762508	A Study of VABu Conditioning Regimen in Allo-HSCT for AML Patients	The First Affiliated Hospital of Soochow University	Not applicable	Not yet recruiting	Leukemia, Myeloid, Acute(AML), Hematopoietic Stem Cell Transplantation (HSCT)	42	China	clinicaltrials.gov
August 12, 2026	NCT07761702	Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML	Shanghai Jiao Tong University School of Medicine	Phase 3	Not yet recruiting	AML (Acute Myelogenous Leukemia)	132		clinicaltrials.gov
August 12, 2026	NCT07761533	PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS	Chaser Therapeutics, Inc.	Phase 1/2	Recruiting	Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome)	29	China	clinicaltrials.gov
August 11, 2026	NCT07758218	Allogeneic iNKT Cell Therapy (agenT-797) After SCT	University of Wisconsin, Madison	Phase 1	Not yet recruiting	Allogenic Stem Cell Transplantation, Myeloid Malignancies, Lymphoid Malignancies, Acute Myeloid Leukemia, Chronic...	22	United States	clinicaltrials.gov
August 11, 2026	NCT07757672	Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.	Institute of Hematology & Blood Diseases Hospital, China	Phase 1/2	Not yet recruiting	AML (Acute Myelogenous Leukemia, HSCT	50		clinicaltrials.gov
August 10, 2026	NCT07755202	Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia	Florian Kuchenbauer	Phase 2	Not yet recruiting	Acute Myeloid Leukemia, AML With FLT3 Mutation	20	Canada	clinicaltrials.gov
August 10, 2026	NCT07754799	A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Acute Myeloid Leukemia (AML)	320		clinicaltrials.gov
August 7, 2026	NCT07751991	A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML	Charm Therapeutics	Phase 1	Recruiting	AML (Acute Myeloid Leukemia)	40	United Kingdom, United States	clinicaltrials.gov
August 7, 2026	NCT07751588	Plasma ctDNA Monitoring in Pediatric Acute Leukemia	Institute of Hematology & Blood Diseases Hospital, China	Observational	Not yet recruiting	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia	25	China	clinicaltrials.gov
August 6, 2026	NCT07749976	GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors	Vitruviae	Phase 1/2	Not yet recruiting	Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor...	108		clinicaltrials.gov
August 5, 2026	NCT07748455	HMA-Venetoclax Induction in Newly Diagnosed AML	Pakistan Blood and Marrow Transplant (PBMT) Group	Phase 2	Not yet recruiting	AML, AML (Acute Myeloid Leukemia)	60	Pakistan	clinicaltrials.gov
August 3, 2026	NCT07743112	A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia	Maxinovel Pty., Ltd.	Phase 2	Recruiting	Acute Myeloid Leukemia	43	China	clinicaltrials.gov
August 3, 2026	NCT07743047	Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality	IRCCS San Raffaele	Observational	Not yet recruiting	Acute Myeloid Leukemia	65		clinicaltrials.gov
July 30, 2026	NCT07737769	Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or...	University of Michigan Rogel Cancer Center	Phase 1	Not yet recruiting	Acute Myeloid Leukemia, Myelodysplastic Syndrome	20	United States	clinicaltrials.gov
July 29, 2026	NCT07735208	Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia	University of Rochester	Phase 2	Not yet recruiting	Acute Myeloid Leukemia	120	United States	clinicaltrials.gov
July 29, 2026	NCT07735117	Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML	Ruijin Hospital	Phase 3	Not yet recruiting	Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)	168		clinicaltrials.gov
July 24, 2026	NCT07726576	Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia	University Hospital, Bordeaux	Phase 1/2	Not yet recruiting	Leukemia, Myeloid, Acute	41	France	clinicaltrials.gov
July 23, 2026	NCT07723703	Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML	Amphista Therapeutics Ltd	Phase 1	Recruiting	Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome	54	United Kingdom, United States	clinicaltrials.gov
July 23, 2026	NCT07722767	A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients	Cullinan Therapeutics Inc.	Phase 1	Not yet recruiting	AML (Acute Myeloid Leukemia)	90	United States	clinicaltrials.gov
July 23, 2026	NCT07722312	S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory...	Servier	Phase 1/2	Not yet recruiting	Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia	80		clinicaltrials.gov
July 22, 2026	NCT07719348	A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies	Servier	Phase 1/2	Not yet recruiting	Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia	64		clinicaltrials.gov
July 21, 2026	NCT07717164	PRAISE-IR Versus CIBMTR Controls	Miltenyi Biomedicine GmbH	Observational	Not yet recruiting	ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)	51	United States	clinicaltrials.gov
July 20, 2026	NCT07712848	DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML	The Second Affiliated Hospital of Kunming Medical University	Phase 3	Recruiting	AML (Acute Myeloid Leukemia)	291	China	clinicaltrials.gov
July 17, 2026	NCT07710781	Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic...	Ossium Health, Inc.	Not applicable	Not yet recruiting	Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic...	300		clinicaltrials.gov
July 17, 2026	NCT07710534	Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN	Virginia Commonwealth University	Phase 2	Recruiting	Relapsed / Refractory AML, High Risk Myelodysplastic Syndrome, High Risk Myeloproliferative Neoplasms	40	United States	clinicaltrials.gov
July 10, 2026	NCT07696481	Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia	Zhujiang Hospital	Early phase 1	Not yet recruiting	Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory...	18	China	clinicaltrials.gov
July 7, 2026	NCT07686965	Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at...	Institute of Hematology & Blood Diseases Hospital, China	Phase 3	Not yet recruiting	Acute Myeloid Leukemia (AML), Maintenance Treatment, Hematopoetic Stem Cell Transplantation	191		clinicaltrials.gov
July 7, 2026	NCT07686107	Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."	Therapeutic Advances in Childhood Leukemia Consortium	Phase 2	Not yet recruiting	Leukemia, Myeloid, Acute	24		clinicaltrials.gov
July 2, 2026	NCT07680868	Caris Chromoseq Data Collection	Caris Science, Inc.	Observational	Recruiting	Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplatic Syndromes...	300	United States	clinicaltrials.gov
June 30, 2026	NCT07676006	A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With...	Grit Biotechnology	Early phase 1	Not yet recruiting	Relapsed/Refractory Acute Myeloid Leukemia (AML)	36	China	clinicaltrials.gov
June 26, 2026	NCT07672262	VA Consolidation in Intermediate-Risk AML	The First Affiliated Hospital of Soochow University	Phase 2	Recruiting	Acute Myeloid Leukemia, Intermediate Risk Acute Myeloid Leukemia, Consolidation Therapy	226	China	clinicaltrials.gov
June 26, 2026	NCT07670130	Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis	The First Affiliated Hospital of Soochow University	Observational	Recruiting	Acute Myeloid Leukemia (AML)	50	China	clinicaltrials.gov
June 25, 2026	NCT07668557	Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia	iCell Gene Therapeutics	Phase 1	Recruiting	Acute Myeloid Leukemia (AML)	18	China	clinicaltrials.gov
June 24, 2026	NCT07664839	Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations	Shen yang	Phase 2	Not yet recruiting	Acute Myeloid Leukemia, NPM1 Mutation, IDH1 Mutation, IDH2 Mutation	148	China	clinicaltrials.gov
June 23, 2026	NCT07663864	Luspatercept for CIA in AML	Guangdong Second Provincial General Hospital	Phase 1/2	Recruiting	Chemotherapy-inducing Anemia	40	China	clinicaltrials.gov
June 22, 2026	NCT07661095	A Study of CRD3874-SI in People With Leukemia	Memorial Sloan Kettering Cancer Center	Phase 1	Recruiting	Acute Myeloid Leukemia, AML, Refractory Acute Myeloid Leukemia	24	United States	clinicaltrials.gov
June 16, 2026	NCT07651176	Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive...	First Affiliated Hospital of Zhejiang University	Phase 2/3	Enrolling by invitation	Acute Myeloid Leukemia, Lisaftoclax	267	China	clinicaltrials.gov
June 16, 2026	NCT07651163	Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for...	First Affiliated Hospital of Zhejiang University	Phase 2/3	Enrolling by invitation	Acute Myeloid Leukemia (AML), Lisaftoclax	450	China	clinicaltrials.gov
June 12, 2026	NCT07645469	FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia	Fred Hutchinson Cancer Center	Phase 1	Recruiting	Acute Myeloid Leukemia	9	United States	clinicaltrials.gov
June 12, 2026	NCT07644481	Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem...	Institute of Hematology & Blood Diseases Hospital, China	Not applicable	Not yet recruiting	AML (Acute Myelogenous Leukemia), Allogeneic Hematopoietic Stem Cell Transplantation Recipient	30		clinicaltrials.gov
June 11, 2026	NCT07643636	Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML	Dongguan People's Hospital	Phase 2	Not yet recruiting	AML (Acute Myeloid Leukemia)	46		clinicaltrials.gov
June 11, 2026	NCT07642453	VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.	Hematology department of the 920th hospital	Phase 2	Not yet recruiting	Acute Myeloid Leukemia (AML)	110		clinicaltrials.gov
June 9, 2026	NCT07634536	Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant	Stanford University	Phase 2	Not yet recruiting	Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes	30	United States	clinicaltrials.gov
June 4, 2026	NCT07627568	Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.	University of Freiburg	Observational	Recruiting	Acute Myeloid Leukemia	20	Germany	clinicaltrials.gov
June 3, 2026	NCT07623616	A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia	Kyowa Kirin Co., Ltd.	Phase 2	Recruiting	Acute Myeloid Leukemia (AML)	6	Japan	clinicaltrials.gov
June 3, 2026	NCT07623187	A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in...	Ipsen	Phase 2/3	Not yet recruiting	Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia	540		clinicaltrials.gov
June 1, 2026	NCT07617363	ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS	Washington University School of Medicine	Phase 1	Not yet recruiting	Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome	36	United States	clinicaltrials.gov
June 1, 2026	NCT07616921	A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia...	University of Washington	Not applicable	Recruiting	Acute Myeloid Leukemia	30	United States	clinicaltrials.gov
May 29, 2026	NCT07616089	Phase I Study of FXS0683 in the Treatment of Blood Tumors	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Phase 1	Recruiting	B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia	228	China	clinicaltrials.gov
May 29, 2026	NCT07613385	Individualized AML Treatment	City of Hope Medical Center	Observational	Recruiting	Relapsed/Refractory Acute Myeloid Leukemia (AML)	20	United States	clinicaltrials.gov
May 26, 2026	NCT07607418	Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS	Ruijin Hospital	Phase 2	Recruiting	AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)	20	China	clinicaltrials.gov
May 26, 2026	NCT07607327	Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)	CareDx	Observational	Enrolling by invitation	AML (Acute Myelogenous Leukemia), MDS (Myelodysplastic Syndrome), CMML	400	United States	clinicaltrials.gov
May 26, 2026	NCT07605949	Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML	UNC Lineberger Comprehensive Cancer Center	Phase 2	Not yet recruiting	Leukemia Acute Myeloid	88	United States	clinicaltrials.gov
May 20, 2026	NCT07598838	Fitness in Elderly AML Patients	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	Observational	Active not recruiting	AML (Acute Myelogenous Leukemia	725	Italy	clinicaltrials.gov
May 20, 2026	NCT07598110	FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION...	Institut Paoli-Calmettes	Phase 2	Not yet recruiting	Acute Myeloid Leukemia	77		clinicaltrials.gov
May 19, 2026	NCT07597590	Digital Patient-Reported Assessment in Older Adults With Acute Leukemia	Fundación para la Investigación Biosanitaria del Principado de Asturias	Not applicable	Not yet recruiting	Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia	20	Spain	clinicaltrials.gov
May 18, 2026	NCT07591649	Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT	Masonic Cancer Center, University of Minnesota	Phase 1/2	Recruiting	Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia	18	United States	clinicaltrials.gov
May 14, 2026	NCT07588360	Haplo-Cord HSCT for AML/MDS	Fujian Medical University Union Hospital	Not applicable	Recruiting	MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)	82	China	clinicaltrials.gov
May 13, 2026	NCT07584889	Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies	Shenzhen University General Hospital	Phase 1/2	Recruiting	B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia	10	China	clinicaltrials.gov
May 13, 2026	NCT07583888	VABu Conditioning in Elderly AML HSCT	The First Affiliated Hospital of Soochow University	Phase 2/3	Recruiting	Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)	20	China	clinicaltrials.gov
May 13, 2026	NCT07583303	BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1...	City of Hope Medical Center	Phase 1	Not yet recruiting	Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	19	United States	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
Institute of Hematology & Blood Diseases Hospital, China	23	November 5, 2026
The First Affiliated Hospital of Soochow University	15	August 13, 2026
Peking University People's Hospital	9	November 9, 2026
First Affiliated Hospital of Zhejiang University	9	October 29, 2026
National Cancer Institute (NCI)	8	October 7, 2026
City of Hope Medical Center	8	May 29, 2026
Ruijin Hospital	7	July 29, 2026
Memorial Sloan Kettering Cancer Center	7	June 22, 2026
M.D. Anderson Cancer Center	6	August 21, 2026
Fred Hutchinson Cancer Center	5	September 14, 2026
Assiut University	5	September 9, 2026
Guangdong Second Provincial General Hospital	4	September 16, 2026
Shanghai Jiao Tong University School of Medicine	4	August 12, 2026
Fondazione IRCCS Policlinico San Matteo di Pavia	4	January 30, 2026
IRCCS Azienda Ospedaliero-Universitaria di Bologna	4	March 20, 2025
Gruppo Italiano Malattie EMatologiche dell'Adulto	3	November 3, 2026
Liping Dou	3	October 27, 2026
The First Affiliated Hospital of Xiamen University	3	August 24, 2026
University of Rochester	3	July 29, 2026
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	3	May 29, 2026

By phase

Phase	New trials	Latest
Phase 2	96	November 9, 2026
Phase 1	89	November 6, 2026
Observational	58	November 5, 2026
Not applicable	52	November 3, 2026
Phase 1/2	36	November 9, 2026
Phase 3	26	November 9, 2026
Early phase 1	15	August 18, 2026
Phase 2/3	12	June 16, 2026
Phase 4	6	August 19, 2026

By country

Country	New trials	Latest
China	130	November 9, 2026
United States	122	November 2, 2026
Italy	30	November 3, 2026
France	22	October 26, 2026
United Kingdom	13	August 7, 2026
Spain	13	May 19, 2026
Germany	12	June 4, 2026
South Korea	10	May 12, 2026
Australia	10	December 29, 2025
Canada	8	August 10, 2026
Taiwan	7	September 4, 2026
Czechia	7	May 6, 2026
Japan	6	June 3, 2026
Denmark	6	February 3, 2026
Belgium	6	November 3, 2025
Poland	6	October 8, 2025
Austria	5	May 12, 2026
Russia	5	January 26, 2026
Egypt	5	November 24, 2025
Brazil	5	October 8, 2025
Israel	4	May 12, 2026
Greece	4	October 8, 2025
Lithuania	4	October 8, 2025
Portugal	4	June 5, 2025
Sweden	3	November 3, 2025

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.